From: E2F4 regulatory program predicts patient survival prognosis in breast cancer
GSE ID | Platform | Cancer type | Number of samples | Source |
---|---|---|---|---|
- | cDNA two channel | Breast | 295 | Vijver et al., 2002 [4] |
GSE1456 | HG-U133A | Breast | 159 | Pawitan et al., 2005 [8] |
GSE2034 | HG-U133A | Breast | 286 | Wang et al., 2005 [5] |
GSE2990 | HG-U133A | Breast | 177 | Sotiriou et al., 2006 [6] |
GSE3494 | HG-U133A | Breast | 260 | Miller et al., 2005 [7] |
GSE6532 | HG-U133A | Breast | 327 | Loi et al., 2008 [33] |
GSE7390 | HG-U133A | Breast | 198 | Desmedt et al., 2007 [34] |
GSE11121 | HG-U133A | Breast | 200 | Schmidt et al., 2008 [35] |
GSE13507 | Illumina beadchip | Bladder | 256 | Kim et al., 2010 [36] |
GSE13041 | HG-U133A | Glioblastoma | 191 | Lee et al., 2008 [37] |
GSE8894 | HG-U133 Plus 2 | Non-small cell lung | 138 | Lee et al., 2008 [38] |
GSE17536 | HG-U133 Plus 2 | Colon | 177 | Smith et al., 2010 [39] |
GSE425 | cDNA two channel | Acute myeloid leukemia | 119 | Bullinger et al., 2004 [40] |
GSE4475 | HG-U133A | Burkitt’s lymphoma | 221 | Hummel et al., 2006 [41] |